Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 328,414
  • Shares Outstanding, K 98,034
  • Annual Sales, $ 30,480 K
  • Annual Income, $ -96,970 K
  • 60-Month Beta 1.70
  • Price/Sales 11.10
  • Price/Cash Flow N/A
  • Price/Book 3.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.20
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.29
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +3.08%
on 05/20/19
3.98 -15.83%
on 05/06/19
-0.45 (-11.84%)
since 04/22/19
3-Month
3.02 +10.93%
on 03/13/19
4.14 -19.08%
on 04/12/19
-0.38 (-10.19%)
since 02/22/19
52-Week
3.02 +10.93%
on 03/13/19
6.30 -46.83%
on 10/02/18
-1.49 (-30.79%)
since 05/22/18

Most Recent Stories

More News
QIAGEN Partners Inovio to Develop Companion Diagnostics

QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

MASI : 140.58 (+1.19%)
QGEN : 38.70 (+0.49%)
INO : 3.35 (-2.90%)
CNMD : 81.50 (+1.05%)
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Inovio Pharmaceuticals Inc. (NASDAQ: INO) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to...

INO : 3.35 (-2.90%)
QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) and Inovio Pharmaceuticals Inc. (NASDAQ:INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making...

QGEN : 38.70 (+0.49%)
INO : 3.35 (-2.90%)
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus

Inovio Pharmaceuticals Inc. (NASDAQ: INO) and Plumbline Life Sciences (XKRX: 222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The...

INO : 3.35 (-2.90%)
Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates

Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.

AZN : 38.61 (+1.93%)
INO : 3.35 (-2.90%)
REGN : 320.09 (+3.27%)
SNY : 42.09 (+2.21%)
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of -3.45% and -36.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

INO : 3.35 (-2.90%)
Inovio: 1Q Earnings Snapshot

PLYMOUTH MEETING, Pa. (AP) _ Inovio Pharmaceuticals Inc. (INO) on Thursday reported a loss of $29.2 million in its first quarter.

INO : 3.35 (-2.90%)
Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic nucleic technology targeted against cancers...

INO : 3.35 (-2.90%)
What's in the Cards for AcelRx (ACRX) This Earnings Season?

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

GNMSF : 181.2500 (+1.18%)
HZNP : 25.57 (-1.46%)
ACRX : 2.90 (-2.03%)
INO : 3.35 (-2.90%)
What's in Cards for Cumberland (CPIX) This Earnings Season?

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

CPIX : 6.40 (+1.59%)
GNMSF : 181.2500 (+1.18%)
HZNP : 25.57 (-1.46%)
INO : 3.35 (-2.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade INO with:

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

2nd Resistance Point 3.55
1st Resistance Point 3.45
Last Price 3.35
1st Support Level 3.29
2nd Support Level 3.23

See More

52-Week High 6.30
Fibonacci 61.8% 5.05
Fibonacci 50% 4.66
Fibonacci 38.2% 4.27
Last Price 3.35
52-Week Low 3.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar